A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors
Author:
Publisher
Elsevier BV
Subject
Radiology Nuclear Medicine and imaging,Oncology,General Medicine
Reference37 articles.
1. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization;Sanmamed;Cell,2019
2. Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development;Oliveira;Curr Oncol Rep.,2020
3. Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?;Chocarro de Erauso;Front Pharmacol.,2020
4. Determinants of Resistance to Checkpoint Inhibitors;Tran;Int J Mol Sci.,2020
5. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies;Galon;Nat Rev Drug Discov.,2019
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. PD‐1: A critical player and target for immune normalization;Immunology;2024-01-25
2. Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies;Theranostics;2024
3. The relationship between autophagy and PD-L1 and their role in antitumor therapy;Frontiers in Immunology;2023-03-15
4. Resveratrol analog, triacetylresveratrol, a potential immunomodulator of lung adenocarcinoma immunotherapy combination therapies;Frontiers in Oncology;2023-02-09
5. Recent Trends in Diagnostic Biomarkers of Tumor Microenvironment;Molecular Imaging and Biology;2022-12-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3